Bristol-Myers Squibb News

Bristol-Myers Squibb Aktie VALOR 914188 / ISIN US1101221083

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

28.05.25	Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE (RTTNews)
09.11.22	Form 4 14272 (RSS)
26.10.22	Form 8-K 14272 (RSS)
22.09.22	Statement of changes in beneficial ownership of securities (RSS)
16.08.22	Tender offer statement by Third Party (RSS)
09.08.22	Tender offer statement by Third Party (RSS)
19.07.22	Tender offer statement by Third Party (RSS)
01.07.22	Tender offer statement by Third Party (RSS)
17.06.22	Tender offer statement by Third Party (RSS)
16.06.22	Annual report of employee stock purchase, savings and similar plans (RSS)
03.06.22	Written communication relating to an issuer or third party (RSS)
04.03.10	Bristol-Myers Squibb to Highlight Strong Pipeline and Execution of BioPharma Strategy in Meeting with Investment Community (Businesswire)
02.03.10	Bristol-Myers Squibb Names Lamberto Andreotti CEO, Effective May 4; James Cornelius to Retire as CEO, Remain as Chairman (Businesswire)
02.03.10	FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients (Businesswire)
28.01.10	Strong Operational and Strategic Performance in Fourth Quarter Caps Transformative 2009 (Businesswire)
25.01.10	European Commission Approves ORENCIA® (abatacept) in Combination with Methotrexate for Children with Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (pJIA) (Businesswire)
02.12.09	New Data on Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 51st Annual Meeting of the American Society of Hematology (Businesswire)
20.11.09	U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years) (Businesswire)
31.10.09	BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis (Businesswire)
23.10.09	Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer (Businesswire)
22.10.09	Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter (Businesswire)
20.10.09	New Data Describe Safety of Subcutaneous Administration of ORENCIA® (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis (Businesswire)
19.10.09	ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration) (Businesswire)
23.07.09	Excellent Performance Highlights Second Quarter for Bristol-Myers Squibb (Businesswire)
12.06.09	ORENCIA® (abatacept) DEMONSTRIERT KONSISTENTE SICHERHEIT UND WIRKSAMKEIT ÜBER 7 JAHRE HINWEG (Businesswire)
12.06.09	ORENCIA® (abatacept) DEMONSTRATES CONSISTENT SAFETY AND EFFECTIVENESS OVER 7 YEARS (Businesswire)
14.05.09	SPRYCEL® (Dasatinib) Shows Potential as Treatment for Prostate Cancer (Businesswire)
27.01.09	Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb (Businesswire)
06.11.08	Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal (Businesswire)
02.11.08	New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B (Businesswire)
28.10.08	Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis (Businesswire)
23.10.08	Bristol-Myers Squibb Continues Excellent Financial Performance Led By Double-Digit Global Net Sales Growth and Strong Earnings Results (Businesswire)
06.10.08	Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner (Businesswire)
01.10.08	U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients (Businesswire)
01.10.08	Thirteen Advocacy Groups Collaborate on New Online Resource Dedicated to Patients with Advanced Breast Cancer (Businesswire)
13.08.08	ADDING MULTIMEDIA NJ, CT, NY & MD School Districts Join Program That Teaches High School Students How Medicines Are Made (Businesswire)
12.06.08	ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis (Businesswire)
13.05.08	Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease (Businesswire)
24.04.08	Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company (PR Newswire)
17.12.07	Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million (PR Newswire)
11.12.07	Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe (Businesswire)
05.12.07	Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community (PR Newswire)
30.11.07	Bristol-Myers Squibb, New Jersey Children's Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS (PR Newswire)
14.11.07	New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer (PR Newswire)
12.11.07	Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) (PR Newswire)
09.11.07	FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML (PR Newswire)
25.10.07	Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2007 (PR Newswire)
18.10.07	European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) (PR Newswire)
17.10.07	Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV (PR Newswire)
17.10.07	Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	608.20	0.33 %	K V
Swisscom	565.50	-0.26 %	K V
Roche Hldg G	260.20	-0.27 %	K V
Part Grp Hldg	1’093.50	-0.36 %	K V
Zurich Insur Gr	576.60	-0.93 %	K V
Swiss Life Hldg	816.20	-1.52 %	K V
Swiss Re	145.55	-1.85 %	K V
Alcon	70.56	-1.95 %	K V
Sonova Hldg	257.70	-2.05 %	K V
CieFinRichemont	155.90	-2.38 %	K V

mehr

11:35		GSK-Chefin zu Handelskonflikt: US-Zölle wären tragbar - Aktie schwächelt trotzdem
28.05.25		Dow Jones 30 Industrial-Titel Merck-Aktie: Über diese Dividendenzahlung können sich Merck-Anleger freuen
28.05.25		Merck-Aktie unbeeindruckt: Darmstädter Merck will bald Zulassung von Pimicotinib beantragen
27.05.25		Novartis-Aktie unbeeindruckt: Novartis startet Übernahme von US-Biotech Regulus Therapeutics
27.05.25		Dow Jones 30 Industrial-Papier Merck-Aktie: So viel hätten Anleger mit einem Investment in Merck von vor 5 Jahren verdient
27.05.25		S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte eine Investition in Pfizer von vor 5 Jahren bedeutet
27.05.25		Aktien-Analyse: Bernstein Research bewertet Merck-Aktie
27.05.25		EURO STOXX 50-Wert Sanofi-Aktie: So viel hätten Anleger mit einem Investment in Sanofi von vor einem Jahr verdient